Dr. Yinghong Wang is a gastroenterologist who specializes in Inflammatory Bowel Disease (IBD), fecal microbiota transplantation (FMT), and cancer immunotherapy induced gastrointestinal (GI) toxicities. She has a strong academic background (M.D., Ph.D., M.Sc.) and has been associated with  Johns Hopkins, Cleveland Clinic, and MD Anderson Cancer Center. Dr. Wang is recognized for her identification of multiple aspects of  cancer immunotherapy-induced GI toxicities and for establishing the current approaches for their treatment.  Locally, she has established the MD Anderson  IBD clinic and FMT service,  is Chair of the Immunotherapy Toxicity Working Group, established  FMT as standard of care for recurrent C. difficile infections in cancer patients, and is the lead contributor to creating a detailed management algorithm for immunotherapy induced colitis.  Over the past 3 years, she served as a guideline panel member for immunotherapy induced colitis in four national and international oncology societies and one gastroenterology society (ASCO, SITC, NCCN, ESMO, AGA) .  She wrote the section on this area in  UPTODATE and published a new book entitled “Managing Immunotherapy Related Organ Toxicities, A Practical Guide” as editor. Dr. Wang and her team achieved a breakthrough in establishing  successful treatment for immunotherapy induced colitis refractory to immunosuppressant by FMT and use of biologics. Her pioneering work was published in Nature Medicine, with great impact in this field with further expansion on the patient volume to > 35 cases with high efficacy of 83%. Further expanding this study, she launched three prospective clinical trials since 2019 and received multiple research grants to validate this approach.  She has over 130 publications (h-index 35) in top peer-reviewed journals that have significantly impacted the current standard practice in managing challenging GI toxicities seen with immunotherapeutic approaches to treat cancer.